New press release out: HCS Pharma, LumiSTAR Biotech & MolDev explore stem cell-derived organoids for drug screening

In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…

Animal tests no longer necessary before drug clinical trials? Let’s make it in 3D in preclinical studies… and with the extracellular matrix!

End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…

New article published for Nanostem project about the interaction between nanoparticles and the blood-brain barrier in vitro

To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route to reach the central nervous system, several strategies have been developed. Among them, researchers try Read more…